# Jaime D. Blais

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jaime-d-blais/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,648 |
| Field | Genetic and Kidney Cyst Diseases |
| h-index | 29 |
| i10-index | 34 |
| Last Known Institution | Janssen (United States) |
| OpenAlex ID | https://openalex.org/A5051197194 |
| Works | 54 |

## Researcher papers

- [ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth](https://scholariq.org/papers/er-stress-regulated-translation-increases-tolerance-to-extreme-hypoxia-and/)
- [Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/tolvaptan-in-later-stage-autosomal-dominant-polycystic-kidney-disease/)
- [Activating Transcription Factor 4 Is Translationally Regulated by Hypoxic Stress](https://scholariq.org/papers/activating-transcription-factor-4-is-translationally-regulated-by-hypoxic-stress/)
- [Perk-Dependent Translational Regulation Promotes Tumor Cell Adaptation and Angiogenesis in Response to Hypoxic Stress](https://scholariq.org/papers/perk-dependent-translational-regulation-promotes-tumor-cell-adaptation-and/)
- [ERO1-β, a pancreas-specific disulfide oxidase, promotes insulin biogenesis and glucose homeostasis](https://scholariq.org/papers/ero1-a-pancreas-specific-disulfide-oxidase-promotes-insulin-biogenesis-and/)
- [Prevalence of autosomal dominant polycystic kidney disease in the European Union](https://scholariq.org/papers/prevalence-of-autosomal-dominant-polycystic-kidney-disease-in-the-european-union/)
- [Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database](https://scholariq.org/papers/clinical-pattern-of-tolvaptan-associated-liver-injury-in-subjects-with-autosomal/)
- [Point-of-care breath test for biomarkers of active pulmonary tuberculosis](https://scholariq.org/papers/point-of-care-breath-test-for-biomarkers-of-active-pulmonary-tuberculosis/)
- [Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial](https://scholariq.org/papers/multicenter-open-label-extension-trial-to-evaluate-the-long-term-efficacy-and/)
- [Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial](https://scholariq.org/papers/effect-of-tolvaptan-in-autosomal-dominant-polycystic-kidney-disease-by-ckd-stage/)

## Researcher topics

- [Genetic and Kidney Cyst Diseases](https://scholariq.org/topics/genetic-and-kidney-cyst-diseases/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Endoplasmic Reticulum Stress and Disease](https://scholariq.org/topics/endoplasmic-reticulum-stress-and-disease/)
- [Pediatric Urology and Nephrology Studies](https://scholariq.org/topics/pediatric-urology-and-nephrology-studies/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Researcher university

- [Janssen (United States)](https://scholariq.org/institutions/janssen-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.